fda compounding semaglutide warning letters october 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these Hims and Hers warns investors

Excess adipose tissue produces inflammatory cytokines, which promote insulin resistance, which promotes further fat storage, which produces more cytokines

Tapering or stopping tirzepatide may also help your body adjust and reduce overlapping side-effect risk

11, 2012, nutritionj.biomedcentral.com/articles/10.1186/1475-2891-11-105

In that study, GLP-1 agonist treatment led to a reduction in oxidative stress, as assessed by measurement of urinary 8-hydroxy-2-deoxyguanosine and renal dihydroethidium staining

While both Wegovy and Ozempic are FDA-approved GLP-1 receptor agonists , they differ considerably in their intended use and dosage levels

But here is where the comparison gets interesting